Attana (ATANA) Q2 2024 earnings summary

Executive summary

• Focused on biosensor development and services for biotech and pharma, with a strong presence in immuno-oncology research.

• H1 2024 saw improved commercial interest in tissue experiments and a strategic focus on existing cancer drug development clients.

• Cost reductions achieved via relocation and staff cuts, offset by one-time costs for equipment write-offs and patent amortizations.

• Q2 revenue slightly exceeded expectations; Q3 expected to be weaker, with Q4 outlook positive if procurement processes proceed.

Financial highlights

• Net sales for H1 2024: 3.0 MSEK, up from 2.9 MSEK year-over-year.

• Operating result for H1 2024: -3.9 MSEK, improved from -6.3 MSEK year-over-year.

• Net result after tax for H1 2024: -5.1 MSEK, compared to -6.7 MSEK year-over-year.

• Earnings per share for H1 2024: -0.0084 SEK, improved from -0.0247 SEK year-over-year.

• Cash and cash equivalents at period end: 2.6 MSEK.

Outlook and guidance

• Q3 2024 expected to be weaker than Q2, but Q4 anticipated to improve due to increased quotation requests.

• Uncertainty remains regarding timing of procurement processes, which may shift revenue to Q1 2025.